Halozyme Therapeutics
HALO
Teradata Corp
TDC
eBay
EBAY
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 40.42%7.39M | 5.17%6.12M | 8.86%6.3M | -41.20%22.87M | -9.27%6M | -39.95%5.26M | -49.67%5.82M | -51.57%5.79M | -9.87%38.89M | -51.57%6.61M |
Selling and administrative expenses | -2.89%1.41M | -26.83%1.36M | -37.26%1.25M | -38.35%6.72M | -27.90%1.41M | -42.30%1.45M | -41.25%1.86M | -38.74%1.99M | -13.45%10.9M | -51.52%1.96M |
-Selling and marketing expense | -5.75%246K | -25.77%265K | -38.70%236K | -58.59%1.2M | -44.86%193K | -68.93%261K | -61.32%357K | -50.32%385K | -3.18%2.89M | -69.49%350K |
-General and administrative expense | -2.26%1.17M | -27.08%1.1M | -36.92%1.02M | -31.05%5.52M | -24.21%1.22M | -28.99%1.19M | -32.99%1.5M | -35.12%1.61M | -16.64%8.01M | -44.39%1.61M |
Research and development costs | 56.96%5.97M | 20.20%4.76M | 33.10%5.05M | -42.31%16.15M | -1.44%4.59M | -39.01%3.81M | -52.85%3.96M | -56.38%3.79M | -8.39%27.99M | -51.60%4.66M |
Operating profit | -40.42%-7.39M | -5.17%-6.12M | -8.86%-6.3M | 41.20%-22.87M | 9.27%-6M | 39.95%-5.26M | 49.67%-5.82M | 51.57%-5.79M | 9.87%-38.89M | 51.57%-6.61M |
Net non-operating interest income expense | -10.97%-354K | -2,342.86%-171K | 45.10%-140K | -8.49%-1.16M | -34.72%-582K | 27.00%-319K | 97.51%-7K | -426.92%-255K | -314.40%-1.07M | -500.00%-432K |
Non-operating interest income | ---- | ---- | ---- | 105.24%548K | ---- | ---- | ---- | ---- | -42.95%267K | ---- |
Non-operating interest expense | 10.97%354K | 2,342.86%171K | ---- | 58.16%1.62M | 170.76%1.04M | -27.00%319K | -97.51%7K | ---- | --1.02M | --383K |
Total other finance cost | ---- | ---- | -45.10%140K | -70.57%93K | ---- | ---- | ---- | 426.92%255K | 1,087.50%316K | ---- |
Other net income (expense) | -56.02%234K | 1,109.09%532K | ||||||||
Gain on sale of security | ---- | ---- | ---- | -56.02%234K | ---- | ---- | ---- | ---- | 1,109.09%532K | ---- |
Income before tax | -38.73%-7.74M | -7.98%-6.29M | -6.59%-6.44M | 39.65%-23.8M | 2.53%-6.35M | 39.34%-5.58M | 50.81%-5.83M | 49.11%-6.04M | 7.45%-39.43M | 51.77%-6.51M |
Income tax | -20.00%20K | -80.00%2K | -72.00%7K | -46.51%69K | -83.64%9K | -66.22%25K | 10K | 25K | 129K | 55K |
Net income | -38.47%-7.76M | -7.83%-6.29M | -6.26%-6.45M | 39.67%-23.87M | 3.21%-6.36M | 39.55%-5.6M | 50.72%-5.84M | 48.90%-6.07M | 7.15%-39.56M | 51.36%-6.57M |
Net income continuous Operations | -38.47%-7.76M | -7.83%-6.29M | -6.26%-6.45M | 39.67%-23.87M | 3.21%-6.36M | 39.55%-5.6M | 50.72%-5.84M | 48.90%-6.07M | 7.15%-39.56M | 51.36%-6.57M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -38.47%-7.76M | -7.83%-6.29M | -6.26%-6.45M | 39.67%-23.87M | 3.21%-6.36M | 39.55%-5.6M | 50.72%-5.84M | 48.90%-6.07M | 7.15%-39.56M | 51.36%-6.57M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -38.47%-7.76M | -7.83%-6.29M | -6.26%-6.45M | 39.67%-23.87M | 3.21%-6.36M | 39.55%-5.6M | 50.72%-5.84M | 48.90%-6.07M | 7.15%-39.56M | 51.36%-6.57M |
Basic earnings per share | 64.12%-1.22 | 68.35%-1.25 | 83.83%-1.37 | 72.19%-16.99 | 60.00%-3.84 | 76.04%-3.4 | 78.42%-3.95 | 55.19%-8.47 | 10.52%-61.09 | 54.93%-9.6 |
Diluted earnings per share | 64.12%-1.22 | 68.35%-1.25 | 83.83%-1.37 | 72.19%-16.99 | 58.65%-3.97 | 76.04%-3.4 | 78.42%-3.95 | 55.19%-8.47 | 10.52%-61.09 | 54.93%-9.6 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |